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Background: The Fas apoptotic pathway has been implicated in type 2 diabetes and cardiovascular disease.
Although a polymorphism (rs7138803; G > A) near the Fas apoptotic inhibitory molecule 2 (FAIM2) locus has been
related to obesity, its association with other cardiovascular risk factors and disease remains uncertain.
Methods: We analyzed the association between the FAIM2-rs7138803 polymorphism and obesity, blood pressure
and heart rate in 7,161 participants (48.3% with type 2 diabetes) in the PREDIMED study at baseline. We also
explored gene-diet interactions with adherence to the Mediterranean diet (MedDiet) and examined the effects of
the polymorphism on cardiovascular disease incidence per diabetes status after a median 4.8-year dietary intervention
(MedDiet versus control group) follow-up.
Results: We replicated the association between the FAIM2-rs7138803 polymorphism and greater obesity risk (OR: 1.08;
95% CI: 1.01-1.16; P = 0.011; per-A allele). Moreover, we detected novel associations of this polymorphism with higher
diastolic blood pressure (DBP) and heart rate at baseline (B = 1.07; 95% CI: 0.97-1.28 bmp in AA vs G-carriers for the
whole population), that remained statistically significant even after adjustment for body mass index (P = 0.012) and
correction for multiple comparisons. This association was greater and statistically significant in type-2 diabetic
subjects (B = 1.44: 95% CI: 0.23-2.56 bmp; P = 0.010 for AA versus G-carriers). Likewise, these findings were also
observed longitudinally over 5-year follow-up. Nevertheless, we found no statistically significant gene-diet interactions
with MedDiet for this trait. On analyzing myocardial infarction risk, we detected a nominally significant (P = 0.041)
association in type-2 diabetic subjects (HR: 1.86; 95% CI:1.03-3.37 for AA versus G-carriers), although this association
did not remain statistically significant following correction for multiple comparisons.
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Conclusions: We confirmed the FAIM2-rs7138803 relationship with obesity and identified novel and consistent
associations with heart rate in particular in type 2 diabetic subjects. Furthermore, our results suggest a possible
association of this polymorphism with higher myocardial infarction risk in type-2 diabetic subjects, although this
result needs to be replicated as it could represent a false positive.
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Obesity is a major determinant of type 2 diabetes. Over
the last decade, multiple genome wide association stud-
ies (GWAs) have identified numerous polymorphisms
associated with body mass index (BMI), and some of
them have also been related to higher type 2 diabetes
risk [1-7]. However, how the majority of these genes
function in affecting anthropometric-related parameters
is unknown. Moreover, both obesity and type 2 diabetes
have been associated with higher blood pressure and
cardiovascular disease risk [8,9]. Currently, to better
understand the possible mechanisms involved, some
studies have also analyzed the association between these
obesity-related genes with cardiovascular risk factors
such as hypertension, metabolic syndrome, etc. [10-13].
The FAIM2 (Fas apoptotic inhibitory molecule 2) is one
of the less well-known genes associated with obesity.
The rs7138803 (G > A) single nucleotide polymorphism
(SNP) located near the FAIM2 locus was described for
the first time to be associated with higher BMI in car-
riers of the minor allele by Thorleifsson et al. [4]. Later,
Speliotes et al. [6] in a larger GWAs confirmed this asso-
ciation and estimated that the increase of BMI per vari-
ant allele would be ~ 0.12 kg/m2. However, the results of
later studies in different populations have been diverse
[14-20], suggesting some heterogeneity of the association
depending on the characteristics of the population ana-
lyzed. FAIM2, also called NMP35 (neural membrane
protein 35), or LFG (lifeguard), is known to codify for an
antiapoptotic protein, highly expressed in the brain that
antagonizes the Fas pathway [21,22]. Fas (CD95 or APO-
1) is a cell surface receptor, expressed in a variety of tis-
sues. FasL is a member of the tumour necrosis factor
superfamily and the natural ligand to Fas [23]. Various
studies have associated both Fas and FasL concentra-
tions with hypertension and cardiovascular risk [24,25],
and there is a study in Chinese subjects showing an as-
sociation between the FAIM2-rs7138803 polymorphism
and diastolic blood pressure [26]. However, there are no
published studies in humans that have analyzed the as-
sociation between the FAIM2-rs7138803 polymorphism
and resting heart rate, which is an independent and
important risk factor of cardiovascular diseases [27-29],
mainly in type 2 diabetic patients [30]. Although, inanimal models, it has been shown that Faim2 is a novel
neuroprotective molecule in the context of cerebral
ischemia [31], there are no studies on humans that have
analyzed the association between FAIM2 polymorphisms
and cerebrovascular disease risk. Only one previous
study, carried out in a Chinese population [32], has
examined the association between the FAIM2-rs7138803
polymorphism and cardiovascular disease, but no statis-
tical association was found. Taking into account that the
Fas apoptotic pathway has been implicated in type 2 dia-
betes and that a high glucose intake can induce vascular
endothelial cell apoptosis and higher risk of myocardial
infarction [33,34], we hypothesized that the association
between the FAIM2-rs7138803 polymorphism and heart
rate and cardiovascular disease would be greater in type
2 diabetic subjects. Additionally, diet may modulate this
association, as one experimental study showing that
nutritional state affects the expression of the Faim2 gene
suggested [35]. Thus, our aims were: 1) To analyze the
association of the FAIM2-rs7138803 polymorphism with
anthropometrical measures, blood pressure and resting
heart rate in the whole population and in type 2 diabetic
subjects at baseline, also analyzing its modulation by
adherence to the MedDiet; 2) To study the longitudinal
association of the polymorphism with heart rate and
with incidence of cardiovascular diseases (stroke and
myocardial infarction) by diabetes status, also analyzing
modulation by intervention with MedDiet.
Methods
Subjects
We analyzed 7,161 participants (3,049 men and 4,112
women) in the PREDIMED (PREvención con DIeta MEDi-
terránea) trial from whom the FAIM2-rs7138803 poly-
morphism was successfully determined. The PREDIMED
study is a multi-center, randomized, controlled clinical trial
(controlled-trials.com number, ISRCTN35739639) aimed at
assessing the effects of the MedDiet on the primary preven-
tion of cardiovascular disease [36]. The completion date of
this study was December 2010 and the total number of
randomized subjects was 7,447. The 7,161 participants
included in the present study did not differ in the main
characteristics from those of the total cohort. Additional file
1: Figure S1 shows the CONSORT flowchart of the trial.
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lations and interim analysis have been fully described else-
where [36-38]. Briefly, from October 2003 physicians in
Primary Care Centers selected high cardiovascular risk
subjects. Eligible subjects were community-dwelling people
(55–80 years of age for men; 60–80 years of age for
women) who fulfilled at least one of two criteria: type 2
diabetes [39] or three or more cardiovascular risk factors as
previously detailed [36-38]. Exclusion criteria included a
personal history of cardiovascular disease, any severe
chronic illness, and drug or alcohol addiction [36]. Partici-
pants were randomly assigned to three interventions: Med-
Diet with extra-virgin olive oil, MedDiet with mixed nuts
and control group (low-fat diet). Participants assigned to
both MedDiet groups received intensive training to follow
the MedDiet and allocations of either extra virgin olive oil
(1 litre/week, for all the family) or mixed nuts (30 g/d) at
no cost [36,37]. Participants assigned to the control diet re-
ceived recommendations on reducing the intake of all types
of fat. A detailed description of the nutritional interventions
has been provided elsewhere [36]. The Institutional Review
Board/Ethics Committee of each participating center
approved the study protocol. All participants provided writ-
ten informed consent. Participants were followed up for a
median of 4.8 years (interquartile range, 2.8 to 5.8 years).
Data were analyzed cross-sectionally (at baseline) as well as
longitudinally (pooling together the MedDiet intervention
groups versus the control group). By December 2010, a
total of 502 participants (7.0%) had been lost to follow-up
for 2 or more years. Dropout rates were higher in the
control group (11%) than in the MedDiet groups (5%)
(Additional file 1: Figure S1). As compared with partici-
pants who remained in the trial, those who dropped out
were younger (by 1.4 years), had a higher BMI and a lower
score for the adherence to the MedDiet as previously de-
tailed elsewhere [36]. The effect of the FAIM2-rs7138803
polymorphism on heart rate was also examined longitudin-
ally analyzing all subjects having heart rate data at baseline,
at 1-year, at 3-years and at 5-years (n = 2,310). The reduc-
tion in the number of cases in the longitudinal analysis was
mainly due no to patients being lost during follow up,
but to the fact that patients were not all recruited in
the same year at the beginning of the study, but pro-
gressively over the following years (from 2003 to 2009)
as previously described [36]. Therefore, individuals
who entered the study in 2003 completed the 5-year
follow-up period in the year 2010, which is when
follow-up ended, whereas those who entered the study
in later years could not complete the 5-year follow-up
period and so were not included in the longitudinal
analyses of the study on heart rate. The Institutional
Review Board/Ethics Committee of each participating
center approved the study protocol. All participants
provided written informed consent.Demographic, clinical, anthropometric and dietary
measurements
The baseline examination included an assessment of
standard cardiovascular risk factors, medication use,
socio-demographic factors and lifestyle variables, as pre-
viously detailed [36,38]. Food consumption was deter-
mined by a validated semi-quantitative food frequency
questionnaire [40]. Adherence to MedDiet at baseline
was assessed by a validated 14-item questionnaire [41].
The final score ranged from 0 to 14. The greater the
score obtained from the questionnaire, the greater the
adherence to the MedDiet. Physical activity was esti-
mated by the Minnesota Leisure-Time Physical Activity
Questionnaire, as previously described [36].
Weight and height were measured with calibrated
scales and a wall-mounted stadiometer, respectively.
BMI was calculated as weight in kilograms divided by
the square of height in meters.
At baseline and yearly thereafter, trained personnel mea-
sured blood pressure and heart rate in triplicate using a
validated semiautomatic oscillometer (Omron HEM-705CP,
Hoofddorp, the Netherlands) with a 5-minute interval
between each measurement with the patients seated and at
rest in a peaceful setting. The means of these measurements
were calculated.
Outcome ascertainment
The primary endpoint was the occurrence of the first
major cardiovascular events and comprised myocardial
infarction, stroke or cardiovascular death [36]. We used
four sources of information to identify end-points: 1) re-
peated contacts with participants; 2) family physicians;
3) yearly review of medical records; and 4) consultation
of the National Death Index. The end-point adjudication
committee, whose members were blind to treatment al-
location, examined all medical records related to end-
points. Only end-points confirmed by the adjudication
committee that occurred between October 1, 2003, and
December 1, 2010 were included in the analyses. The
criteria for adjudicating primary outcomes are detailed
elsewhere [36].
Biochemical determinations, DNA extraction and
genotyping
At baseline, blood samples were obtained from each par-
ticipant after an overnight fast and were frozen at -80ºC.
Fasting glucose, total cholesterol, triglycerides, HDL-C
and LDL-C were measured using standard methods as
previously described [37].
Genomic DNA was extracted from buffy-coat with the
MagNaPure LC DNA Isolation Kit (Roche Diagnostics,
Mannheim, Germany). The rs7138803 (G >A) polymor-
phism near FAIM2 was genotyped on a 7900HT Sequence
Detection System (Applied Biosystems, FosterCity, CA,
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assay. The calling rate was 98%. Genotype frequencies did
not deviate from Hardy-Weinberg equilibrium expectations
(P = 0.378).
Statistical analyses
Data were analyzed both at baseline and longitudinally
in the intervention trial. Chi-square tests were used to
test differences in percentages. T and ANOVA tests were
applied to compare crude means of continuous variables
among genotypes at baseline. Multivariable adjustments
for continuous variables were carried out by linear re-
gression analysis and regression coefficients (B) were es-
timated. Models were sequentially adjusted for age, sex,
center, type 2 diabetes, total energy intake, adherence to
MedDiet, alcohol, tobacco, physical activity, hyperten-
sion, and medications (antihypertensive, lipid-lowering
and hypoglycemic drugs) as indicated. Antihypertensive
medication included angiotensin-converting enzymes
(ACE) inhibitors (48% of the population took these), di-
uretics (21% of the population) and other antihyperten-
sive drugs (beta blockers, calcium channel blockers, etc.)
regardless of the dosage, as previously described [36].
Three dummy variables (taking or not taking the corre-
sponding drug regardless of the dosage) were considered
for the antihypertensive medication including ACE in-
hibitors, diuretics and other antihypertensive drugs. In
addition a dummy variable (taking or not taking) for
lipid-lowering drugs and two dummy variables (one for
insulin and other for oral antidiabetic agents) were in-
cluded in the adjustment for medications. Hypertension
was defined as systolic blood pressure > =140 mm Hg or
diastolic blood pressure > =90 mmHg or under anti-
hypertensive medication. The FAIM2-rs7138803 poly-
morphism was first tested as additive for continuous
traits analyzed. However, when the differences between
heterozygous and homozygous subjects for the variant
A-allele were very small, a recessive model was selected
(for heart rate). A dichotomous variable for the pre-
randomization adherence to MedDiet was created using
the sample means as cut-off values (9 points). Obesity
was defined as BMI > = 30 kg/m2. Logistic regression
methods were also used to estimate the contribution
of the FAIM2-rs7138803 polymorphism to predict
obesity. In addition, BMI was categorized into four ca-
tegories (BMI < 25 kg/m2; 25–30 kg/m2; 30–35 kg/m2
and > =35 kg/m2). Heart rate in beats per minute (bmp)
was also categorized into five categories (<=60, 60–70,
70–80, 80–90 and > =90 bmp) for categorical analyses.
The interaction between the FAIM2-rs7138803 poly-
morphism and adherence to the MedDiet in determining
BMI, blood pressure and resting heart rate at baseline
was tested in multivariable regression models (linear or
logistic for categorical) including the correspondingmain effects and interaction terms. Subgroup analyses
stratified by type 2 diabetes status were carried out ac-
cording to our “a priori” hypothesis and aim. The effect
of the FAIM2-rs7138803 polymorphism on heart rate in
the whole population and stratified by type 2 diabetes
status was also examined longitudinally analyzing all
subjects having heart rate data at baseline, at 1-year, at
3-years and at 5-years (n = 2,310) in a multivariable model
of repeated measures with interactions terms after adjust-
ment for the dietary intervention and the indicated covari-
ates. Dietary intervention was considered as a dichotomous
variable pooling together the MedDiet intervention groups
versus the control group after having checked the homo-
geneity of the effect in the two MedDiet groups). In
addition, we analyzed the interaction term between the
FAIM2-rs7138803 and dietary intervention on changes in
heart rate at 5-years by linear regression analysis with
multivariable adjustment. Finally, we examined the asso-
ciation between the FAIM2-rs7138803 polymorphism and
cardiovascular events (total cardiovascular events, myo-
cardial infarction or stroke) in the whole population and
in type 2 diabetic subjects by Cox regression models
with the length of follow-up as the primary time variable
and adjustment for the dietary intervention and the
other covariates as indicated. The exposure time was
calculated as the time between randomization and the
date of a major cardiovascular event, the date when
completing the last interview, December 1st 2010, or
the date at death, whichever came first. Hazard ratios
(HR) with 95% confidence intervals (CI) for the
FAIM2-rs7138803 polymorphism (recessive model) for
cardiovascular diseases were calculated in the popula-
tion as a whole. In addition, we carried out the stratified
analysis by type-2 diabetes status. Analyses were based
on the intention-to-treat principle. In multivariable
model 1 we adjusted for sex, age, center and dietary
intervention. Multivariable model 2 included additional
adjustments for BMI, total energy intake, alcohol, smo-
king, type-2 diabetes, medications and physical activity.
Additional adjustments for baseline hypertension were
also undertaken. The proportionality of hazards in de-
termining the main outcomes in the PREDIMED study
was tested with the use of time-varying covariates as
previously described [36]. Here we graphically checked
the assumption of proportional hazards for the genetic
factor (FAIM2) by looking at the Log-Log plot of sur-
vival. We obtained parallel lines for the curves of geno-
types in all the models fitted. Finally, Kaplan-Meier
survival curves were plotted to estimate the probability
of remaining free of myocardial infarction during
follow-up. Statistical analyses were performed with the
SPSS package, version 18.0 (SPSS, Chicago, IL). All tests
were two-tailed and the nominal significance level was
set at a P-value <0.05. In addition, the Bonferroni
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isons. Our approach consisted of using an adjusted alpha
level equal to the nominal alpha level (0.05), divided by the
number of new hypothesis tested. With the aim of achiev-
ing a balance between type I and type II errors, we have
chosen to undertake the Bonferroni correction considering
the three new groups of variables that we were investigating
(heart rate, blood pressure and cardiovascular diseases).
Anthropometric measures were not included in the correc-
tion because in this case we were not dealing with a new
hypothesis of association. Thus, the adjusted alpha was
0.05/3 = 0.017. The significance of each original (un-
corrected) test was assessed at this level. Thus, a P-value
<0.017 was considered to be statistically significant taking
into account the correction for multiple comparisons.
Results
Prevalence of the FAIM2-rs7138803 (G > A) genotypes
was: 42.2% GG, 44.9%GA and 12.3% AA. Table 1 showsTable 1 Demographic, clinical, lifestyle and genetic character
groups
Total MedDi
(n = 7,161) (n
Age (years) 67.0 ± 6.2 67.0
BMI (Kg/m2) 30.0 ± 3.8 29.9
Waist circumference (cm) 100.4 ± 10.6 100.2
Female sex: n,% 4112 (57.4) 1448
Systolic blood pressure (mmHg) 149.4 ± 20.8 148.5
Diastolic blood pressure (mmHg) 83.4 ± 11.0 83.1
Heart rate (bpm) 71.4 ± 11.2 71.4
Current smokers: n,% 1003 (14.0) 345
Type 2 diabetes: n,% 3462 (48.3) 1238
Hypertension: n,% 5928 (82.8) 2026
Dyslipidemia: n,% 5172 (72.2) 1766
FAIM2-rs7138803 (G > A) : n,%
GG 3019 (42.2) 1022
GA 3235 (45.2) 1132
AA 907 (12.7) 315
Energy intake (kcal/d) 2274 ± 606 2286
Total fat (% energy) 39.2 ± 6.8 39.3
Saturated fat (% energy) 10.0 ± 2.3 10.0
MUFA (% energy) 19.5 ± 4.6 19.6
Proteins (% energy) 16.6 ± 2.8 16.6
Carbohydrates (% energy) 41.9 ± 7.1 41.7
Adherence to the MedDiet 8.6 ± 2.0 8.7
Alcohol consumption (g/d) 8.4 ± 14.2 8.6
Physical activity (MET-min/day) 231 ± 239 232
Values are mean ± SD for continuous variables and number (%) for categorical varia
MUFA, Monounsaturated fatty acids; MedDiet, Mediterranean diet; EVOO, extra virgdemographic, clinical, lifestyle and genetic characteristics
of the 7,161 participants in the PREDIMED study ac-
cording to the randomly assigned dietary intervention
groups at baseline. We did not find statistically significant
differences on analyzing demographic, lifestyle (dietary
intake, smoking, drinking and physical activity), clinical
(prevalence of type 2 diabetes, hypertension and medica-
tions) or biochemical parameters at baseline among the
FAIM2-rs7138803 (Additional file 1: Table S1).
Association between the FAIM2-rs7138803 polymorphism
anthropometrical variables, blood pressure and heart rate
at baseline
We observed a statistically significant association
between the FAIM2-rs7138803 polymorphism and BMI
(Badjusted = 0.15: 95% CI: 0.02-0.27 kg/m
2 per variant-
allele; P = 0.023) in the additive model after adjustment
for sex, age, centre, type 2 diabetes, hypertension and
medications (Table 2). We also found additive effects inistics of the study participants at baseline by intervention
et with EVOO MedDiet nuts Control group
= 2,469) (n = 2,363) (n = 2,329)
± 6.2 66.7 ± 6.1 67.3 ± 6.3
± 3.7 29.7 ± 3.8 30.2 ± 4.0
± 10.4 100.2 ± 10.5 100.8 ± 10.8
(58.6) 1271 (53.8) 1393 (59.8)
± 20.8 149.6 ± 20.4 150.1 ± 21.1
± 10.9 83.7 ± 10.9 83.3 ± 11.1
± 11.1 71.2 ± 11.1 71.6 ± 11.3
(14.0) 339 (14.3) 319 (13.7)
(50.1) 1096 (46.8) 1128 (48.4)
(82.1) 1954 (82.7) 1948 (83.6)
(71.5) 1730 (73.2) 1676 (72.0)
(41.4) 1000 (42.3) 997 (42.8)
(45.8) 1062 (44.9) 1041 (44.7)
(12.8) 301 (12.7) 291 (12.5)
± 606 2317 ± 610 2219 ± 598
± 6.9 39.4 ± 6.5 39.0 ± 6.8
± 2.2 10.0 ± 2.2 10.0 ± 2.3
± 4.6 19.5 ± 4.3 19.3 ± 4.7
± 2.9 16.5 ± 2.7 16.6 ± 2.8
± 7.2 41.5 ± 7.0 42.3 ± 7.2
± 2.0 8.7 ± 2.0 8.4 ± 2.1
± 14.4 9.2 ± 15.0 7.5 ± 13.1
± 231 247 ± 246 215 ± 241
bles. BMI indicates body mass index.
in olive oil.
Table 2 Association between the FAIM2-rs7138803 and anthropometrical measures, blood pressure and heart rate
FAIM2 (G > A) genotypes
GG (n = 3,019) GA (n = 3,235) AA (n = 907) Additive model Recessive model
Mean SD Mean SD Mean SD P1 B1 (95% CI) P2 P3 B1 (95% CI) P1 P2 P3
Weight (kg) 76.4 ± 11.9 76.9 ± 11.9 77.3 ± 12.1 0.026 0.46 (0.06-0.87) 0.059 0.59 (−0.24-1.42) 0.164 0.191
BMI (kg/m2) 29.9 ± 3.8 30.0 ± 3.9 30.1 ± 3.9 0.055 0.13 (−0.01-0.26) 0.023 0.20 (−0.07-0.47) 0.147 0.066
Waist circumference (cm) 100.3 ± 10.5 100.3 ± 10.6 101.0 ± 10.9 0.167 0.26 (−0.11-0.62) 0.141 0.68 (−0.07-1.42) 0.075 0.085
SBP (mmHg) 149.2 ± 20.8 149.4 ± 20.9 149.9 ± 20.1 0.414 0.30 (−0.42-1.01) 0.783 0.889 0.57 (−0.89-2.03) 0.443 0.761 0.896
DBP (mmHg) 82.9 ± 10.9 83.4 ± 10.9 84.3 ± 11.2 0.001 0.61 (0.24-1.00) 0.006 0.015 1.12 (0.36-1.89) 0.004 0.009 0.017
Heart rate (bpm) 71.1 ± 11.2 71.2 ± 10.9 72.3 ± 11.4 0.029 0.43 (0.04-0.81) 0.039 0.048 1.07 (0.29-1.86) 0.007 0.010 0.012
Prevalence of
obesity (%)
45.2 47.5 49.1 0.021 0.136
Obesity risk,
OR (95% CI)
1 (ref.) 1.10 (0.99-1.21) 1.17 (1.01-1.35) 0.021 1.08 (1.01-1.16) 0.011 1.11 (0.97-1.28) 0.136 0.070
Means, prevalence, odds ratios (OR), and regression coefficients (B).
Values are means and standard deviations (SD), odds ratio (OR) and 95% confidence intervals (CI) or regression coefficients (B) and 95% CI.
B: Regression coefficient per-variant allele effects in the additive model (genotypes coded as 0, 1 and 2 according to the number of minor alleles for additive effects) and regression coefficients for homozygotes for
the variant allele versus the other genotypes in the recessive model (genotypes coded as 0 for GG and GA and 1 for AA).
SBP: Systolic blood pressure. DBP: Diastolic blood pressure.
1: Unadjusted P values for the polymorphism for the comparison of means or OR (in an additive or recessive models as indicated).
2: Models adjusted for sex, age, center, type 2 diabetes, medications (antihypertensive drugs, lipid-lowering drugs and antidiabetic drugs) and diagnosed hypertension.
3: Model 2 additionally adjusted for BMI. Further adjustment for total energy intake, adherence to Mediterranean diet and physical activity did not change the statistical significance of these associations.
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(ORadjusted: 1.08; 95% CI: 1.01-1.17 per variant-allele;
P: 0.011). Likewise, we obtained a statistically significant
association with diastolic blood pressure (DBP) in the
additive model adjusted for covariates that remained
significant after BMI adjustment (P = 0.015). Moreover,
we observed a novel association between this poly-
morphism and resting heart rate which was greater in
the recessive model, and that remained statistically sig-
nificant after multivariable adjustment including BMI
(P = 0.012). Additional adjustment of the model for
DBP did not attenuate the statistical significance of this
association (P = 0.010). All these association were statisti-
cally significant not only at the nominal P-value (P < 0.05)
but also after correction for multiple comparisons taking
the level of P < 0.017 into account.
In the stratified analysis by type-2 diabetes status (48%
diabetic patients), we observed that the association of
the polymorphism with heart rate was greater and statis-
tically significant (P = 0.010) in type-2 diabetic subjects
(Badjusted = 1.44: 95% CI: 0.23-2.56 bmp for AA versus
carriers of the G-allele). No significant association was
found in non-diabetics (Badjusted: 0.62: 95% CI: -0.47-1.69
bmp; P = 0.258, in non-diabetics for AA versus G-carriers).
However, in terms of BMI, we found no heterogeneity of
the effects of the polymorphism by diabetes status, obtain-
ing similar associations in type 2 diabetic subjects as in
non-diabetics (not shown).
We also analyzed (Additional file 1: Table S2) the
association of the FAIM2-rs7138803 polymorphism
with different categories of BMI and observed that
the association increased with BMI categories (P-for
trend: 0.008). Categorizing heart rate (Table 3) into five
categories (<=60, 60–70, 70–80, 80–90 and > =90 bpm),
we also observed that the association with the poly-
morphism was greater as the heart rate categoryTable 3 Association between the FAIM2-rs7138803 polymorp
FAIM2 (G > A) genotypes Unadjust
Heart rate GG + GA (n = 6,049) AA (n = 888) OR* (95%
<60 bpm (%) 90.1 9.9 1 (ref)
60-70 bmp (%) 87.3 12.7 1.32 (1.05-
70-80 bmp (%) 86.4 13.6 1.43 (1.13-
80-90 bmp (%) 86.1 13.9 1.46 (1.12-
> = 90 bmp (%) 85.0 15.0 1.60 (1.13-
P for trend* 0.002
Prevalence and odds ratios (OR). Unadjusted and adjusted models.
Values are prevalences in%, odds ratio (OR) and 95% confidence intervals (CI).
OR: Odds ratio for the corresponding category of heart rate in comparison with the
(recessive model) in comparison with carriers of the major allele.
*: P-value of the Chi2 test for linear trend.
1: Unadjusted P values for the polymorphism (recessive model).
2: Models adjusted for sex, age, center, type 2 diabetes, hypertension, physical activ
energy intake.
3: Model 2 additionally adjusted for BMI.increased (P-for linear trend: 0.002). Thus, prevalence
of AA homozygotes was 9.9% in subjects having a heart
rate < =60 bpm, whereas its prevalence was 15.0% among
subjects having a heart rate > =90 bpm (ORadjusted: 1.66,
95% CI: 1.13-2.43; P = 0.009 for AA homozygotes ver-
sus G-allele carriers) in the multivariable adjusted
model including BMI.
Modulation by adherence to the MedDiet at baseline
of the associations between the FAIM2-rs7138803
polymorphism and anthropometrical variables, DBP and
heart rate
We did not observe any statistically significant gene-diet
interaction in the multivariable adjusted models (by sex,
age, centre, type 2 diabetes, medications, hypertension,
smoking, drinking, physical activity and total energy
intake) between adherence to the MedDiet (two catego-
ries based on the population mean of 9 points) at baseline
and the FAIM2-rs7138803 polymorphism in determining
BMI (P-interaction: 0.716) (Additional file 1: Figure S2A),
waist circumference (P-interaction: 0.658), obesity
(P-interaction = 0.679), DBP (P-interaction: 0.346) or
heart rate (P-interaction: 0.371) (Additional file 1: Figure S2B).
Stratified analysis per hypertension of the association
between the FAIM2-rs7138803 polymorphism and DBP
and heart rate
Although in this study, prevalence of diagnosed hyperten-
sion at baseline was very high (82.8%), we analyzed whether
the association of the polymorphism with DBP (Additional
file 1: Figure S3A) and heart rate (Additional file 1: Figure
S3B) differed by hypertension status. We obtained no statis-
tically significant interactions and observed homogeneous
results across the strata. Statistically significant differences
for the polymorphism were detected in subjects with hyper-
tension because this group had a higher sample size.hism and categories of heart rate
ed1 Adjusted2 Adjusted3
CI) P1 OR* (95% CI) P2 OR* (95% CI) P3
1 (ref) 1 (ref)
1.67) 0.019 1.27 (1.00-1.60) 0.051 1.26 (1.00-1.60) 0.052
1.82) 0.003 1.46 (1.14-1.87) 0.003 1.45 (1.13-1.86) 0.003
1.92) 0.006 1.47 (1.10-1.97) 0.009 1.46 (1.10-1.96) 0.011
2.27) 0.008 1.65 (1.13-2.42) 0.010 1.66 (1.13-2.43) 0.009
reference category (<60 bpm) for homozygous subjects for the variant allele
ity, medications, smoking, drinking, adherence to Mediterranean diet and total
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polymorphism and heart rate
Given that that heart rate was the parameter in which
we found the most novel association, we wanted to study
whether the association between the FAIM2-rs7138803
polymorphism and heart rate was maintained over time
and how the intervention with MedDiet (MedDiet
groups vs control group after having observed no he-
terogeneity in the MedDiet groups) influenced that
association. We used longitudinal data from 5-year
follow-up analyzing data for all subjects having heart
rate measured at baseline, at 1-year, at 3-years and at 5-
years (n = 2,310) in a model for repeated measures. Preva-
lence of the FAIM2-rs7138803 genotypes in this group was
41.3% GG, 44.8% GA and 13.9% AA, very close to the
population as a whole. The mean age was the same (67.1 ±
6.0 years) as in the population as a whole. There were
slight differences in other demographic or clinical vari-
ables. Thus, in this group prevalence of women was 56.4%,
prevalence of type 2 diabetes was 45.1%, mean BMI was
29.7 ± 3.6 kg/m2, mean SBP was 84.4 ± 10.8 mmHg and
mean heart rate was 70.5 ± 10.8 bpm.
Having firstly tested an additive model and observed
similar effects in heterozygous and in homozygous sub-
jects, we employed the recessive model. For the whole
population, we detected a statistically significant effect
of the polymorphism in determining the heart rate over
the 5-year follow-up period (P = 0.004 in the model ad-
justed for intervention with MedDiet, sex, age, centre,70
71
72
73
74
75
76
77
0 1
Time follow-up
H
ea
rtr
at
e 
(bp
m)
P-interaction: rs7138803 x Diet x
P for the FAIM2-rs7138803: 0.00
*P:0.049 *P:0.012
Figure 1 Longitudinal effect of the FAIM2-rs7138803 polymorphism o
rate in beats per minute (bpm) depending on the polymorphism (GG + GA
diabetic subjects at baseline having data for all four measurements (n = 1,0
ANOVA model with interaction terms adjusted for dietary intervention (Me
activity. Adjusted P values for the interaction term among the polymorphis
polymorphism are shown. *Adjusted P values for the polymorphism at eve
sion at baseline did not change the statistical significance of the results.baseline BMI, type 2 diabetes, hypertension, medica-
tions, smoking and physical activity). We did not obtain
a significant interaction between the FAIM2-rs7138803
polymorphism and intervention with MedDiet in the
follow-up for the whole population (P-interaction: 0.392,
in the adjusted model). Neither did we obtain significant
interactions between these variables in determining
changes in heart rate (P = 0.215).
In the analysis stratified by diabetes status (n = 1,076 sub-
jects with type-2 diabetes and n = 1,234 non-diabetics), we
found that the longitudinal association between the
FAIM2-rs7138803 polymorphism and heart rate was higher
and statistically significant in subjects with type-2 diabetes
(P = 0.002 for the polymorphism in the longitudinal analysis
of the multivariable adjusted model) (Figure 1). This longi-
tudinal association remained statistically significant after
correction for multiple comparisons. No statistically signifi-
cant association for the polymorphism in the follow-up was
detected in non-diabetics (P = 0.135). Even in type 2 dia-
betic subjects we did not detect a significant interaction
between the polymorphism and the intervention with
MedDiet (P-interaction = 0.587, multivariable adjusted) in
the follow-up.
Association between FAIM2-rs7138803 polymorphism
and incidence of cardiovascular events and mortality after
4.8-years follow-up
After a median follow-up of 4.8 years (interquartile
range, 2.8 to 5.8 years), 268 major cardiovascular events3 5
GG+GA
AA
 (years)
 Time: 0.587
2
*P:0.005
*P:0.012
n heart rate in type 2 diabetic subjects. Adjusted means of heart
versus AA) at baseline, 1, 3 and 5-years of follow-up in all type 2
76). Adjusted means were estimated from a repeated-measures
dDiet versus control), sex, age, BMI, medications, smoking, and physical
m, time, and dietary intervention as well for the overall effect of the
ry specific time point. Further adjustment of the model for hyperten-
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http://www.cardiab.com/content/13/1/5occurred among the 7,161 participants analyzed (30,360
person-years of observation). Of these, 135 were strokes,
100 myocardial infarctions and the others were cardio-
vascular deaths. Firstly, we longitudinally analyzed the
association of the polymorphism with the incidence of
cardiovascular events and adjusted the model for dietary
intervention (MedDiets and control group). Additional
file 1: Table S3 of the Supporting Online Material shows
the HRs for total cardiovascular events, stroke and myo-
cardial infarction. In the whole population, we did notHRAAvsG-carriers: 1.57, 95%
Whole population
HRAAvsG-carriers: 1.86, 95%
Type2 diabetic subjects
A
B
Figure 2 Cumulative myocardial infarction free-survival by the FAIM2
and in type 2 diabetic subjects (B) (n = 3,462). Cox regression models wit
(G-allele carriers versus AA) adjusted by dietary intervention group, sex, age
intake, alcohol, smoking and physical activity. The P-values for the FAIM2
adjusted models.observe a significant association between the FAIM2-
rs7138803 polymorphism (in the recessive model) and
myocardial infarction either in the basic model or in the
model adjusted for BMI (HRadjusted: 1.57, 95% CI: 0.96-
2.62). In the analysis stratified by type 2 diabetes, we
observed a nominally significant association in type 2
diabetes patients (HRadjusted:1.86; 95% CI:1.03-3.37;
P = 0.041 in AA versus G-carriers). However, this asso-
ciation did not remain statistically significant following
correction for multiple comparisons. Figure 2 shows CI (0.96-2.62); P=0.069
GG+GA
GG+GA
AA
AA
 CI (1.03-3.37); P=0.041
-rs7138803 polymorphism in the whole population (A) (n = 7,161)
h outcome of myocardial infarction and the rs7138803 polymorphism
, centre, type 2 diabetes, hypertension, medications, BMI, total energy
-rs7138803 polymorphism were obtained from the multivariable
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FAIM2-rs7138803 polymorphism in the whole population
(A) and in type-2 diabetic subjects (B).
In the study of the modulation by the MedDiet
(MedDiet versus control group) of the effects of the
FAIM2-rs7138803 polymorphism on the incidence of
cardiovascular events, we did not find significant results.
None of the interaction terms between MedDiet interven-
tion and the polymorphism reached the nominal statistical
significance (not shown). Although, we have sample size
limitations to detect gene-diet interaction terms as statisti-
cally significant, this lack of significance seems to be derived
from homogeneous results. Thus, in the case of myocardial
infarction, a similar trend to a greater risk was observed in
AA subjects compared with G-carriers both in the control
group (HR: 1.66, 95% CI: 0.70-3.81) as in the MedDiet
intervention groups (HR: 1.59; 95% CI: 0.85-2.99).
Discussion
In this study on high cardiovascular risk subjects (48%
patients with type 2 diabetes) from a Mediterranean
population, we found, as in other studies [4,6,8,18,20,42],
that the variant allele of the FAIM2-rs7138803 poly-
morphism was associated with higher obesity risk.
Furthermore, our results support the observations of
Paternoster et al. [7] and Sandholt et al. [20] who found
that this polymorphism was associated with higher de-
grees of obesity (BMI > 35). Although it is known that
the FAIM2 gene codifies an evolutionary conserved
inhibitor of Fas-mediated apoptosis [21-23] and the
apoptotic pathways are higher in obesity [43,44], the
mechanisms by which this association occurs are not
known. As we have found for the first time, a strong as-
sociation between this polymorphism and resting heart
rate, as well as with DBP, we can hypothesize on the in-
fluence of the FAIM2-rs7138803 polymorphism. Thus,
the minor allele may give rise to a variant resulting in
less FAIM2 gene expression or activity. Hence minor al-
lele carriers seem to be less protected against apoptosis
and appear to present higher levels (despite their magni-
tude being small) of harmful cardiovascular risk pheno-
types (greater obesity, higher DBP and higher resting
heart rate), contributing over time increasing the poten-
tial risk of myocardial infarction. Although the functions
of the FAIM2 in the different metabolic diseases are not
well known, it is known that the FAIM2 acts as an antia-
poptotic protein which would inhibit Fas-mediated cell
death [45]. Moreover a growing body of evidence has
shown that Fas-mediated apoptosis is involved in athero-
sclerosis progression [25,45,46]. A study in rats [47] sug-
gested that the augmented expression of apoptotic
signalling by the Fas/FasL pathway plays an important
role in hypertensive nephrosclerosis. In humans it has
also been reported that hypertensive subjects present agreater expression of the FAS gene [48]. In addition,
greater serum concentrations of both Fas and
FasL have been associated with type-2 diabetes, hyper-
tension, and cardiovascular disease [24,33,34,45,49,50].
In our study, we have described for the first time a sta-
tistically significant association between the FAIM2-
rs7138803 polymorphism and higher DBP, which was in-
dependent from BMI and remained significant even after
correction for multiple comparisons. Although in a pre-
vious study on Chinese subjects [26] the FAIM2-
rs7138803 polymorphism was associated with higher
DBP in children, this association did not remain statisti-
cally significant after adjustment for BMI. Moreover, as
far as we know, no previous study has reported an asso-
ciation between the FAIM2-rs7138803 polymorphism
and heart rate, this association being greater and statisti-
cally significant in type 2 diabetic subjects. Moreover, we
not only observed this association at baseline but also
after analyzing the association of this polymorphism
with heart rate longitudinally. The fact that this novel
association was found consistently during the 5 years of
follow-up in a sub-group of individuals provides greater
consistency to this association.
On the other hand, when we studied the modulation
of these effects by the MedDiet we did not observe any
statistically significant interaction either in the study at
baseline or following intervention with MedDiet over
4.8 years follow-up. Future studies are therefore required
to better characterize the possible interactions with
more specific dietary components. Numerous studies
have reported that increased heart rate is a predictor of
cardiovascular events and specifically of myocardial in-
farction [29,51-54]. In our study, we observed that the
polymorphism was nominally (P < 0.041) associated with
higher risk of myocardial infarction in type 2 diabetes
subjects. This would be in line with previous studies that
have reported higher apoptosis in type 2 diabetic sub-
jects [33,34,55], greater association between increased
heart rate and cardiovascular morbid-mortality in type-2
diabetes subjects [29,30,56] and with studies showing
that apoptosis in cardiomyocytes is a very important risk
factor in triggering myocardial infarction [57,58]. How-
ever, in our study this association did not remain
statistically significant after correction for multiple com-
parisons. This correction is a hotly debated issue in bio-
medical literature, many authors being opposed to such
corrections because of the increase in false negative re-
sults. Only one previous study [32], has examined the
association between the FAIM2-rs7138803 polymorph-
ism and cardiovascular disease, and no statistical associ-
ation was found. There are many differences between
our study and the Chinese population analyzed and
further research is needed into this issue. Another of the
polymorphisms associated with obesity in recent GWAs
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been associated with higher cardiovascular risk regard-
less of BMI [59], so providing new evidence of the pleio-
tropic effects of obesity-related polymorphisms.
Limitations
Our study has several limitations, one of them being the
relatively low number of cardiovascular events (myocar-
dial infarction and stroke) that reduces the statistical
power for detecting statistically significant associations be-
tween the FAIM2 polymorphism and cardiovascular events
as well as to detect gene-diet interactions between the poly-
morphism and MedDiet intervention in determining car-
diovascular events. In line with this observation, we may
also have statistical power limitations to detect gene-diet
interaction in determining heart rate in the follow-up be-
cause only a sub-group of subjects had data at 5-y. At base-
line, our sample size consisting of 7,161 subjects was high
and allowed us to detect as statistically significant differ-
ences in heart rate or DBP around unit. These associations
although statistically significant were small in magnitude
and may be clinically non-relevant.
Conclusions
In conclusion, the results of our study confirm the associ-
ation between the FAIM2-rs7138803 polymorphism and
obesity risk, being greater for higher degrees of obesity.
Moreover we provide new data on the association between
this polymorphism and higher DBP and heart rate regar-
dless of BMI, these associations being higher in subjects
with type 2 diabetes. In addition, the association of the
polymorphism with heart rate was consistently found over
the follow-up, adding more evidence to this novel associ-
ation. All of this may contribute to the fact that homozy-
gous subjects for the variant allele tended to have a higher
risk of myocardial infarction than the other genotypes in
type 2 diabetic subjects. This association, although nomin-
ally significant did not pass the correction for multiple
comparisons and needs to be replicated in further studies.
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